The Biologics News and Reports Portal

Show Cart

Immuno-Oncology

Results 1 - 9 of 9

Oct 2019 Flat-Rate Subscription to La Merie Publishing Reports

4,000.00 €

Nov 2018 MerTK Inhibitors – Target Pipeline List 11/2018

100.00 €

Jul 2018 Report Package Immuno-Oncology: Inhibitory and Stimulatory Immunomodulators

1,440.00 €

2,400.00 €

(Discount: 40.00%)

Jul 2018 Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-β, CXCR4, CSF-1R, CD47-SIRPα, adenosine pathway & STING 2018

800.00 €

Jul 2018 Competitor Analysis: CD40, GITR, OX40, 4-1BB, CD27, ICOS & Other Immune Checkpoint Activators 2018

500.00 €

Jun 2018 Competitor Analysis: CTLA-4, LAG-3, TIM-3, TIGIT & Other Immune Checkpoint Inhibitors 2018

500.00 €

Jun 2018 Competitor Analysis: PD-1 and PD-L1 Immune Checkpoint Inhibitors 2018

600.00 €

Oct 2017 Report Package: Immunotherapy with Oncolytic Viruses and mRNA Vaccines & Therapeutics

3,080.00 €

4,400.00 €

(Discount: 30.00%)

Jan 2017 The Oncolytic Virus Landscape 2017: an analysis of pipeline, stakeholders, deals, industry trends & opportunities

2,150.00 €

Shopping cart

Cart empty

Shopping cart

Cart empty

Latest report

Competitor Analysis: Next Wave Biosimilar Antibodies of Lucentis, Eylea, Xolair, Prolia, Stelara, Soliris and More

Featured Products

RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

Bispecific Antibodies for Immuno-Oncology & Other Diseases

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

Immuno-Oncology

Oct 2019 Flat-Rate Subscription to La Merie Publishing Reports

Nov 2018 MerTK Inhibitors – Target Pipeline List 11/2018

Jul 2018 Report Package Immuno-Oncology: Inhibitory and Stimulatory Immunomodulators

Jul 2018 Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-β, CXCR4, CSF-1R, CD47-SIRPα, adenosine pathway & STING 2018

Jul 2018 Competitor Analysis: CD40, GITR, OX40, 4-1BB, CD27, ICOS & Other Immune Checkpoint Activators 2018

Jun 2018 Competitor Analysis: CTLA-4, LAG-3, TIM-3, TIGIT & Other Immune Checkpoint Inhibitors 2018

Jun 2018 Competitor Analysis: PD-1 and PD-L1 Immune Checkpoint Inhibitors 2018

Oct 2017 Report Package: Immunotherapy with Oncolytic Viruses and mRNA Vaccines & Therapeutics

Jan 2017 The Oncolytic Virus Landscape 2017: an analysis of pipeline, stakeholders, deals, industry trends & opportunities

Shopping cart

Latest report

Featured Products

Latest Target Pipeline

Shopping cart

Latest report

Featured Products

Latest Target Pipeline

La Merie Biologics

FREE Weekly News Bulletin

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing